U.S. markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.97-1.05 (-4.04%)
At close: 04:00PM EDT
25.00 +0.03 (+0.12%)
After hours: 07:10PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close26.02
Bid24.95 x 800
Ask26.07 x 800
Day's Range24.75 - 26.14
52 Week Range13.60 - 63.68
Avg. Volume736,129
Market Cap1.561B
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SWTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SpringWorks Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 03/29/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Benzinga

    HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

    Ayala Pharmaceuticals Inc (NASDAQ: Ayala) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the stock with a price target of $18. The analyst says that Ayala's initial data is encouraging in the context of the clinical devel

  • Benzinga

    SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

    HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80% and 87% of medical oncologists believe that nirogacestat compares favorably to Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) and that they are willing to switch current patients to nirogacestat, respectively. The analysts for

  • Zacks

    SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

    SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.